Nanoparticle-based drug delivery systems have been developed to improve the efficacy and
reduce the systemic toxicity of a wide range of drugs. Although clinically approved …

Background The rapidly expanding clinical adaptation of prostate-specific membrane
antigen (PSMA)-targeted PET imaging in the evaluation of patients with prostate cancer has …

Purpose Since the clinical introduction of 68 Ga-PSMA-11 PET/CT, this imaging method has
rapidly spread and is now regarded as a significant step forward in the diagnosis of …

Purpose Since the introduction of positron emission tomography (PET) imaging with 68 Ga-
PSMA-HBED-CC (= 68 Ga-DKFZ-PSMA-11), this method has been regarded as a significant …

The prostate-specific membrane antigen (PSMA) has received increased consideration
during the past few years as an excellent target for both imaging and therapy of prostate …

Background: Stratifying prostate cancer (PCa) patients into risk groups at time of initial
diagnosis enabling a risk-adapted disease management is still a major clinical challenge …

Neuroendocrine cells are one of the epithelial populations in the prostate. Neuroendocrine
differentiation (NED) has been observed in prostate cancer. In addition to small cell …

The use of prostate-specific membrane antigen (PSMA)-directed applications in modern
prostate cancer management has evolved rapidly over the past few years, helping to …

Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer, and
small-molecule radiopharmaceuticals targeting PSMA rapidly detect the location and extent …

Prostate cancer (PCa) patients are risk-stratified on the basis of clinical stage and PSA level
at diagnosis and the Gleason Score (GS) in prostate biopsy. However, these parameters are …